RxDoctor Payments Data

Anders Berg

Clinical Pathology/Laboratory Medicine · Boston, MANPI 1730251950

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $10,250 of the $12,938 with a category attached, or 79.2%. Fisher Scientific Company L.L.C. accounts for 79.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $6,375 and has fallen 92.3% since, to $490 in 2025.

$12,938in general payments, 2019–2025

Across 15 payments — averaging $862.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fisher Scientific Company L.L.C.$10K
  • Diasorin Inc.$2K
  • Kaneka Medical America LLC$379
  • BD$348
  • Abbott$176
  • Vertex$125
  • plus $160 from 2 others

What the payments were for

  • Consulting fees$1,84814%
  • Speaking & faculty fees$10,25079%
  • Food & beverage$8406%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Fisher Scientific Company L.L.C.4$10,250
Diasorin Inc.1$1,500
Kaneka Medical America LLC1$379
BD1$348
Abbott4$176
Vertex1$125
Biocartis US, Inc1$91
E.r. Squibb & Sons, L.L.C.2$69

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,938 in reported general payments places this provider in the 85th percentile of 27 clinical pathology/laboratory medicine providers in Massachusetts.

See all clinical pathology/laboratory medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$337,999
Medicare patients
5,227
Services billed
18,576

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other clinical pathology/laboratory medicine in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →